Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,444 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach.
Botticelli A, Cirillo A, Pomati G, Cortesi E, Rossi E, Schinzari G, Tortora G, Tomao S, Fiscon G, Farina L, Scagnoli S, Pisegna S, Ciurluini F, Chiavassa A, Amirhassankhani S, Ceccarelli F, Conti F, Di Filippo A, Zizzari IG, Napoletano C, Rughetti A, Nuti M, Mezi S, Marchetti P. Botticelli A, et al. Among authors: marchetti p. Cancer Immunol Immunother. 2023 Jul;72(7):2217-2231. doi: 10.1007/s00262-023-03384-9. Epub 2023 Mar 3. Cancer Immunol Immunother. 2023. PMID: 36869232 Free PMC article.
BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models.
Capalbo C, Ricevuto E, Vestri A, Ristori E, Sidoni T, Buffone O, Adamo B, Cortesi E, Marchetti P, Scambia G, Tomao S, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A, Giannini G. Capalbo C, et al. Among authors: marchetti p. Ann Oncol. 2006 Jun;17 Suppl 7:vii34-40. doi: 10.1093/annonc/mdl947. Ann Oncol. 2006. PMID: 16760289 Free article.
Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
Giannini G, Capalbo C, Ristori E, Ricevuto E, Sidoni T, Buffone A, Cortesi E, Marchetti P, Scambia G, Tomao S, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A. Giannini G, et al. Among authors: marchetti p. Breast Cancer Res Treat. 2006 Nov;100(1):83-91. doi: 10.1007/s10549-006-9225-9. Epub 2006 May 9. Breast Cancer Res Treat. 2006. PMID: 16847550
Prevalence of BRCA1 and BRCA2 genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer families.
Buffone A, Capalbo C, Ricevuto E, Sidoni T, Ottini L, Falchetti M, Cortesi E, Marchetti P, Scambia G, Tomao S, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A, Giannini G. Buffone A, et al. Among authors: marchetti p. Breast Cancer Res Treat. 2007 Dec;106(2):289-96. doi: 10.1007/s10549-007-9499-6. Epub 2007 Feb 28. Breast Cancer Res Treat. 2007. PMID: 17333342
Continuous, low-dose capecitabine for patients with recurrent colorectal cancer.
Romiti A, Onesti CE, Roberto M, Barucca V, Tomao S, D'Antonio C, Durante V, Milano A, Falcone R, Di Rocco R, Righini R, Marchetti P. Romiti A, et al. Among authors: marchetti p. Med Oncol. 2015 Mar;32(3):54. doi: 10.1007/s12032-015-0496-z. Epub 2015 Feb 1. Med Oncol. 2015. PMID: 25638466 Free article. Clinical Trial.
Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort.
Mazzuca F, Borro M, Botticelli A, Mazzotti E, Marchetti L, Gentile G, La Torre M, Lionetto L, Simmaco M, Marchetti P. Mazzuca F, et al. Among authors: marchetti p, marchetti l. Oncotarget. 2016 Apr 12;7(15):20612-20. doi: 10.18632/oncotarget.7991. Oncotarget. 2016. PMID: 26967565 Free PMC article.
1,444 results